Keywords: gpc, biotech, satraplatin, enters, ph, ii, taxol

GPC Biotech's satraplatin enters Ph II as Taxol combo

Article | 19 December 2005

Print This

German drugmaker GPC Biotech AG says that a Phase II study evaluating its lead drug candidate, satraplatin, in combination with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in